Catalyst Wire Dossier Catalyst Wire Dossier

Pegylated interferon alfa-2b (MK-4031)

pegylated interferon alfa-2b · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Pegylated interferon alfa-2b (MK-4031), covering 2015-02-11 to 2015-02-11. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370) [Phase 1]

See pricing